Global Anti-nuclear Antibody (ANA) Testing Market 2017-2021
About Anti-Nuclear Antibody (ANA) Testing
Antibodies that attack healthy proteins in the nucleus cells are called antinuclear antibodies. When a person has an autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus (SLE), the immune system produces antibodies that will attach to the cells, often causing damage to them. Some of the ANA tests are EUROPLUS ANA Mosaic 20A, QUANTA Lite ANA, BioPlex 2200 ANA Screen. The global ANA testing market is expected to benefit from the growing incidence of several autoimmune diseases worldwide.
Technavio’s analysts forecast the global anti-nuclear antibody (ANA) testing market to grow at a CAGR of 7.13 % during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global anti-nuclear antibody (ANA) testing market for 2017-2021. To calculate the market size, the report considers the new installations/sales/volume/value and replacement/ services of anti-nuclear antibody testing market.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Anti-Nuclear Antibody (ANA) Testing Market 2017-2021
Technavio recognizes the following companies as the key players in the global anti-nuclear antibody (ANA) testing market: Abbott Laboratories, Alere, Bio-Rad Laboratories, and Thermo Fisher Scientific.
Other Prominent Vendors in the market are: Antibodies Incorporated, Biocom Biotech, Erba Diagnostics, F. Hoffmann-La Roche, HOB Diagnostics, HUMAN Diagnostics, IMMCO, ImmunArray, Phadia, Seramun Diagnostica, and Trinity Biotech.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is shift from monoplex to multiplex testing. The focus on multiplex testing is increasing, particularly in the area of IVD, owing to the increased need for effective diagnosis. Autoimmune diseases are chronic conditions that collectively affect around 5% to 8% of the US population. The individuals who develop organ-specific autoimmune disease have a high likelihood of developing additional autoimmune disorders. This has fueled the need for new technologies that can evaluate multiple immune reactivities in a small sample volume.”
According to the report, one of the major drivers for this market is increased prevalence of autoimmune diseases. Autoimmune diseases can affect any organ or system in the body, with the symptoms varying among disease types. There are about 80 types of autoimmune diseases in the world. Rheumatoid arthritis, Lupus, Celiac disease, and multiple sclerosis are some of the autoimmune diseases.
Further, the report states that one of the major factors hindering the growth of this market is limitations of autoimmune disease diagnostics. The limitations of autoimmune disease diagnostics in terms of key parameters such as accuracy pose a challenge to the market. The accuracy of autoimmune disease diagnostics determines the quality of results. Any discrepancy in this parameter will be unproductive to end-users, thereby impacting adoption rates. There are only a few tests that can potentially offer quality results. These tests allow rapid decision making and administration of suitable therapies for treating individuals with autoimmune diseases.
Abbott Laboratories, Alere, Bio-Rad Laboratories, Thermo Fisher Scientific, Antibodies Incorporated, Biocom Biotech, Erba Diagnostics, F. Hoffmann-La Roche, HOB Diagnostics, HUMAN Diagnostics, IMMCO, ImmunArray, Phadia, Seramun Diagnostica, and Trinity Biotech.